EUREPA V 1/0.3 (Repaglinide (1mg) + Voglibose (0.3mg))

Eurepa-V 1/0.3 Tablet is a pharmaceutical formulation that combines two active ingredients aimed at managing type 2 diabetes mellitus effectively. This medication assists individuals in regulating their elevated blood sugar levels that can occur after meals. It is particularly beneficial for patients who have not achieved adequate glycemic control despite following a prescribed diet and using other antidiabetic medications. The administration of Eurepa-V 1/0.3 is recommended immediately after meals, with the specific dosage determined by a healthcare professional. It is important for patients to adhere to their doctor’s instructions and not discontinue the medication without consultation, as this could lead to a rise in blood glucose levels, increasing the risk of severe health issues such as kidney failure and vision loss. If a dose is missed, patients should not take it between meals but should resume with the next scheduled dose post-mealtime. Doubling the dosage to compensate for a missed one is not advisable. This treatment should be part of a comprehensive management plan that includes a nutritious diet, regular physical activity, and weight management as directed by a healthcare provider. Some individuals may experience transient side effects such as gas, diarrhea, abdominal discomfort, decreased blood sugar levels, and skin reactions. These effects are typically mild and resolve without intervention. However, if symptoms persist or worsen, it is essential to seek medical advice. Regular monitoring of blood sugar levels is advised during therapy.